Head to Head Comparison: Stryker (SYK) vs. Its Peers
Stryker (NYSE: SYK) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Stryker to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.
Stryker pays an annual dividend of $1.70 per share and has a dividend yield of 1.1%. Stryker pays out 36.3% of its earnings in the form of a dividend. As a group, “Medical Devices & Implants” companies pay a dividend yield of 1.3% and pay out 42.2% of their earnings in the form of a dividend. Stryker has increased its dividend for 6 consecutive years.
Earnings & Valuation
This table compares Stryker and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Stryker||$11.33 billion||$1.65 billion||32.43|
|Stryker Competitors||$1.67 billion||$207.58 million||87.48|
Stryker has higher revenue and earnings than its rivals. Stryker is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Stryker and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Stryker’s rivals have a beta of 0.47, meaning that their average stock price is 53% less volatile than the S&P 500.
Institutional & Insider Ownership
75.0% of Stryker shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 7.4% of Stryker shares are held by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of recent ratings for Stryker and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Stryker presently has a consensus target price of $152.37, suggesting a potential upside of 0.40%. As a group, “Medical Devices & Implants” companies have a potential upside of 39.83%. Given Stryker’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Stryker has less favorable growth aspects than its rivals.
Stryker beats its rivals on 9 of the 15 factors compared.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.